Merck (MRK) Reports Phase 3 KEYNOTE-756 Trial Met Primary Endpoint streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Pembrolizumab plus chemotherapy led to significant improvement in pathological complete response rate for high-risk, early-stage ER+/HER2- breast cancer.
Breast Cancer Foundation NZ is urging Pharmac to widen access to an already-funded treatment for Kiwi women with advanced breast cancer, as the drug-buying agency today opens consultation on a drug switch proposal. Pharmac is considering replacing Herceptin .
The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in.